113 related articles for article (PubMed ID: 26384085)
1. Smoking and philadelphia-negative chronic myeloproliferative neoplasms.
Lindholm Sørensen A; Hasselbalch HC
Eur J Haematol; 2016 Jul; 97(1):63-9. PubMed ID: 26384085
[TBL] [Abstract][Full Text] [Related]
2. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.
Sørensen AL; Hasselbalch HC
Leuk Res; 2016 Feb; 41():27-35. PubMed ID: 26718091
[TBL] [Abstract][Full Text] [Related]
3. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
[TBL] [Abstract][Full Text] [Related]
4. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
5. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.
Allahverdi N; Yassin M; Ibrahim M
Cancer Control; 2021; 28():10732748211046802. PubMed ID: 34645293
[TBL] [Abstract][Full Text] [Related]
6. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia.
Arefi M; Robledo C; Peñarrubia MJ; García de Coca A; Cordero M; Hernández-Rivas JM; García JL
Eur J Haematol; 2014 Nov; 93(5):422-8. PubMed ID: 24813417
[TBL] [Abstract][Full Text] [Related]
7. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
[TBL] [Abstract][Full Text] [Related]
8. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
9. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
Hultcrantz M; Wilkes SR; Kristinsson SY; Andersson TM; Derolf ÅR; Eloranta S; Samuelsson J; Landgren O; Dickman PW; Lambert PC; Björkholm M
J Clin Oncol; 2015 Jul; 33(20):2288-95. PubMed ID: 26033810
[TBL] [Abstract][Full Text] [Related]
10. Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms.
Tolstrup Larsen R; Tang LH; Brochmann N; Meulengracht Flachs E; Illemann Christensen A; Hasselbalch HC; Zwisler AD
Eur J Haematol; 2018 Jun; 100(6):550-559. PubMed ID: 29464777
[TBL] [Abstract][Full Text] [Related]
11. Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?
Elbæk MV; Sørensen AL; Hasselbalch HC
Leuk Lymphoma; 2016 Aug; 57(8):1793-9. PubMed ID: 26879691
[TBL] [Abstract][Full Text] [Related]
12. [Myeloproliferative neoplasms related glomerulopathy].
Paule R; Ponsoye M; Gueutin V; Deray G; Izzedine H
Rev Med Interne; 2013 Jun; 34(6):369-72. PubMed ID: 23357690
[TBL] [Abstract][Full Text] [Related]
13. Autoimmunity and the risk of myeloproliferative neoplasms.
Kristinsson SY; Landgren O; Samuelsson J; Björkholm M; Goldin LR
Haematologica; 2010 Jul; 95(7):1216-20. PubMed ID: 20053870
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
15. Working environment and myeloproliferative neoplasm: A population-based case-control study following a cluster investigation.
Heavner K; Gross-Davis CA; Frank AL; Newschaffer C; Klotz J; Burstyn I
Am J Ind Med; 2015 Jun; 58(6):595-604. PubMed ID: 25880722
[TBL] [Abstract][Full Text] [Related]
16. Determining the role of smoking in myeloproliferative neoplasms: is it a matter of picking the right control group?
Pulte D
Eur J Haematol; 2016 Jul; 97(1):3-4. PubMed ID: 26518720
[No Abstract] [Full Text] [Related]
17. The aetiology and burden of myeloproliferative neoplasms in the United Kingdom: the MyelOproliferative neoplasmS: an In-depth case-control (MOSAICC) study protocol.
Abutheraa N; Tarburn EL; McShane CM; Duncombe A; McMullin MF; Anderson LA
BMC Cancer; 2023 Dec; 23(1):1207. PubMed ID: 38062390
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Roaldsnes C; Holst R; Frederiksen H; Ghanima W
Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
[TBL] [Abstract][Full Text] [Related]
19. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.
Pettersson H; Knutsen H; Holmberg E; Andréasson B
Eur J Haematol; 2015 Feb; 94(2):152-6. PubMed ID: 25039361
[TBL] [Abstract][Full Text] [Related]
20. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
